Clinical Trial Update: BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study) [Phase 3]

View source ↗

Summary

Phase 3 INSPIRE study of BMN 701 in rhGAA-exposed subjects with late-onset Pompe disease was terminated and results were posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Late-onset Pompe Disease

Drugs mentioned

• BMN 701

Snippet

Sponsor: BioMarin Pharmaceutical | Conditions: Late-onset Pompe Disease | Phase 3 | Status: TERMINATED | Results posted: 2018-06-14